Characterisation of gut, lung, and upper airways microbiota in patients with non-small cell lung carcinoma: Study protocol for case-control observational trial

Rea Bingula, Marc Filaire, Nina Radosevic-Robin, Jean-Yves Berthon, Annick Bernalier-Donadille, Marie-Paule Vasson, Emilie Thivat, Fabrice Kwiatkowski, Edith Filaire, Rea Bingula, Marc Filaire, Nina Radosevic-Robin, Jean-Yves Berthon, Annick Bernalier-Donadille, Marie-Paule Vasson, Emilie Thivat, Fabrice Kwiatkowski, Edith Filaire

Abstract

Background: Several studies have confirmed the important role of the gut microbiota in the regulation of immune functions and its correlation with different diseases, including cancer. While brain-gut and liver-gut axes have already been demonstrated, the existence of a lung-gut axis has been suggested more recently, with the idea that changes in the gut microbiota could affect the lung microbiota, and vice versa. Likewise, the close connection between gut microbiota and cancer of proximal sites (intestines, kidneys, liver, etc.) is already well established. However, little is known whether there is a similar relation when looking at world's number one cause of death from cancer-lung cancer.

Objective: Firstly, this study aims to characterise the gut, lung, and upper airways (UAs) microbiota in patients with non-small cell lung cancer (NSCLC) treated with surgery or neoadjuvant chemotherapy plus surgery. Secondly, it aims to evaluate a chemotherapy effect on site-specific microbiota and its influence on immune profile. To our knowledge, this is the 1st study that will analyse multi-site microbiota in NSCLC patients along with site-specific immune response.

Methods: The study is a case-controlled observational trial. Forty NSCLC patients will be divided into 2 groups depending on their anamnesis: Pchir, patients eligible for surgery, or Pct-chir, patients eligible for neoadjuvant chemotherapy plus surgery. Composition of the UAs (saliva), gut (faeces), and lung microbiota (from broncho-alveolar lavage fluid (BALF) and 3 lung pieces: "healthy" tissue distal to tumour, peritumoural tissue and tumour itself) will be analysed in both groups. Immune properties will be evaluated on the local (evaluation of the tumour immune cell infiltrate, tumour classification and properties, immune cell phenotyping in BALF; human neutrophil protein (HNP) 1-3, β-defensin 2, and calprotectin in faeces) and systemic level (blood cytokine and immune cell profile). Short-chain fatty acids (SCFAs) (major products of bacterial fermentation with an effect on immune system) will be dosed in faecal samples. Other factors such as nutrition and smoking status will be recorded for each patient. We hypothesise that smoking status and tumour type/grade will be major factors influencing both microbiota and immune/inflammatory profile of all sampling sites. Furthermore, due to non-selectivity, the same effect is expected from chemotherapy.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Study flowchart. BALF = broncho-alveolar lavage fluid, CT = chemotherapy, D = day, Pchir = the group of patients undergoing surgery, Pct-chir = the group of patients undergoing chemotherapy and surgery. ∗performed as a part of patient's standard medical care if decided by his/her physician.

References

    1. Brownawell AM, Caers W, Gibson GR, et al. Prebiotics and the health benefits of fiber: current regulatory status, future research, and goals. J Nutr 2012;124:962–74.
    1. Carding S, Verbeke K, Vipond DT, et al. Dysbiosis of the gut microbiota in disease. Microb Ecol Heal Dis 2015;26:26191doi:10.3402/mehd.v26.26191.
    1. Samuelson DR, Welsh DA, Shellito JE. Regulation of lung immunity and host defense by the intestinal microbiota. Front Microbiol 2015;6:1–4.
    1. Bingula R, Filaire M, Radosevic-Robin N, et al. Desired turbulence? Gut-Lung axis, immunity, and lung cancer. J Oncol 2017;2017doi:10.1155/2017/5035371.
    1. Madan JC, Koestle DC, Stanton BA, et al. Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures. MBio 2012;3: doi:10.1128/mBio.00251-12.
    1. Trompette A, Gollwitzer ES, Yadava K, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med 2014;20:159–66.
    1. Mazmanian SK, Cui HL, Tzianabos AO, et al. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005;122:107–18.
    1. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science 2015;336:1268–73.
    1. Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018;359:91–7.
    1. Wasserman H. Cancer Facts and Statistics. Am Cancer Soc 2015;19–21.
    1. Sze MA, Tsuruta M, Yang S-WJ, et al. Changes in the bacterial microbiota in gut, blood, and lungs following acute LPS instillation into mice lungs. PLoS One 2014;9:e111228doi:10.1371/journal.pone.0111228.
    1. Sze MA, Dimitriu PA, Suzuki M, et al. Host response to the lung microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015;192:438–45.
    1. Segal LN, Clemente JC, Tsay J-CJ, et al. Enrichment of lung microbiome with supraglottic taxa is associated with increased pulmonary inflammation. Microbiome 2013;1:19doi:10.1186/2049-2618-1-19.
    1. Lee SH, Sung JY, Yong D, et al. Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions. Lung Cancer 2016;102:89–95.
    1. Yu G, Gail MH, Consonni D, et al. Characterizing human lung tissue microbiota and its relationship to epidemiological and clinical features. Genome Biol 2016;17:163doi:10.1186/s13059-016-1021-1.
    1. Farup PG, Rudi K, Hestad K. Faecal short-chain fatty acids - a diagnostic biomarker for irritable bowel syndrome? BMC Gastroenterol 2016;16:51doi:10.1186/s12876-016-0446-z.
    1. Tufman A, Huber RM, Völk S, et al. Interleukin-22 is elevated in lavage from patients with lung cancer and other pulmonary diseases. BMC Cancer 2016;16:409doi:10.1186/s12885-016-2471-2.
    1. Matanić D, Beg-Zec Z, Stojanović D, et al. Cytokines in patients with lung cancer. Scand J Immunol 2003;57:173–8.
    1. Li J, Wang Z, Mao K, et al. Clinical significance of serum T helper 1/T helper 2 cytokine shift in patients with non-small cell lung cancer. Oncol Lett 2014;8:1682–6.
    1. Kim HO, Kim H-S, Youn J-C, et al. Serum cytokine profiles in healthy young and elderly population assessed using multiplexed bead-based immunoassays. J Transl Med 2011;9:113doi:10.1186/1479-5876-9-113.
    1. Langhorst J, Junge A, Rueffer A, et al. Elevated human β-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol 2009;104:404–10.
    1. David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014;505:559–63.
    1. Elsevier-Masson, Ferry M, Mischlich D, Alix E, et al. Nutrition de La Personne âgée - Aspects Fondamentaux, Cliniques et Psycho-Sociaux. 2018;. Accessed January 18,.
    1. Trung NT, Hien TTT, Huyen TTT, et al. Enrichment of bacterial DNA for the diagnosis of blood stream infections. BMC Infect Dis 2016;16:235doi:10.1186/s12879-016-1568-1.
    1. Godon J, Zumstein E, Dabert P, et al. Molecular microbial diversity of an anaerobic digestor as determined by small-subunit rDNA sequence analysis. Apllied Environ Microbiol 1997;63:2802–13.
    1. Dickson RP, Erb-downward JR, Prescott HC, et al. Cell-associated bacteria in the human lung microbiome. Microbiome 2014;2:1–0.
    1. Fink J, Mathaba LT, Stewart GA, et al. Moraxella catarrhalis stimulates the release of proinflammatory cytokines and prostaglandin E 2 from human respiratory epithelial cells and monocyte-derived macrophages. FEMS Immunol Med Microbiol 2006;46:198–208.
    1. Levin TR. The best laid plans: adaptation is an essential part of going from efficacy research to program implementation. Gastroenterology 2017;152:693–4. doi:10.1053/j.gastro.2017.01.025.
    1. Mortaz E, Adcock IM, Ricciardolo FLM, et al. Anti-inflammatory effects of Lactobacillus Rahmnosus and Bifidobacterium breve on cigarette smoke activated human Macrophages. PLoS One 2015;10:e0136455doi:10.1371/journal.pone.0136455.
    1. Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015;350:1084–9.
    1. Wu D, Hou C, Li Y, et al. Analysis of the bacterial community in chronic obstructive pulmonary disease sputum samples by denaturing gradient gel electrophoresis and real-time PCR. BMC Pulm Med 2014;14:1–7.
    1. Daillère R, Vétizou M, Waldschmitt N, et al. Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. Immunity 2016;45:931–43.
    1. Furet J-P, Firmesse O, Gourmelon M, et al. Comparative assessment of human and farm animal faecal microbiota using real-time quantitative PCR. FEMS Microbiol Ecol 2009;68:351–62.
    1. Dick LK, Field KG, Dick K, et al. Rapid estimation of numbers of fecal bacteroidetes by use of a quantitative PCR assay for 16S rRNA genes. Appl Environ Microbiol 2004;70:5695–7.
    1. Guo X, Xia X, Tang R, et al. Development of a real-time PCR method for Firmicutes and Bacteroidetes in faeces and its application to quantify intestinal population of obese and lean pigs. Lett Appl Microbiol 2008;47:367–73.
    1. Mühling M, Woolven-Allen J, Murrell JC, et al. Improved group-specific PCR primers for denaturing gradient gel electrophoresis analysis of the genetic diversity of complex microbial communities. ISME J 2008;2:379–92.
    1. Layton A, McKay L, Williams D, et al. Development of Bacteroides 16S rRNA gene TaqMan-based real-time PCR assays for estimation of total, human, and bovine fecal pollution in water. Appl Environ Microbiol 2006;72:4214–24.
    1. Kurakawa T, Ogata K, Matsuda K, et al. Diversity of intestinal Clostridium coccoides group in the Japanese population, as demonstrated by reverse transcription-quantitative PCR. PLoS One 2015;10:e0152753.
    1. Tana C, Umesaki Y, Imaoka A, et al. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 2010;22:512–9. e114-5.
    1. Yan X, Yang M, Liu J, et al. Discovery and validation of potential bacterial biomarkers for lung cancer. Am J Cancer Res 2015;5:3111–22.
    1. Dalwai F, Spratt DA, Pratten J. Use of quantitative PCR and culture methods to characterize ecological flux in bacterial biofilms. J Clin Microbiol 2007;45:3072–6.
    1. Haugland RA, Varma M, Sivaganesan M, et al. Evaluation of genetic markers from the 16S rRNA gene V2 region for use in quantitative detection of selected Bacteroidales species and human fecal waste by qPCR. Syst Appl Microbiol 2010;33:348–57.
    1. McOrist AL, Warhurst M, McOrist S, et al. Colonic infection by Bilophila wadsworthia in pigs. J Clin Microbiol 2001;39:1577–9.
    1. Collado MC, Derrien M, Isolauri E, et al. Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly. Appl Environ Microbiol 2007;73:7767–70.
    1. Huijsdens XW, Linskens RK, Mak M, et al. Quantification of bacteria adherent to gastrointestinal mucosa by real-time PCR. J Clin Microbiol 2002;40:4423–7.
    1. Ramirez-Farias C, Slezak K, Fuller Z, et al. Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii. Br J Nutr 2009;101:541–50.
    1. Le Leu RK, Winter JM, Christophersen CT, et al. Butyrylated starch intake can prevent red meat-induced O6-methyl-2-deoxyguanosine adducts in human rectal tissue: a randomised clinical trial. Br J Nutr 2015;114:220–30.
    1. Malinen E, Rinttila T, Kajander K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005;100:373–82.
    1. Daillère R, Vétizou M, Waldschmitt N, et al. Enterococcus hirae and Barnesiella intestinihominis facilitate Cyclophosphamide-Induced therapeutic immunomodulatory effects. Immunity 2016;45:931–43.
    1. Silva-Junior WP, Martins AS, Xavier PCN, et al. Etiological profile of early neonatal bacterial sepsis by multiplex qPCR. J Infect Dev Ctries 2016;10: doi:10.3855/jidc.7474.
    1. Chien Y-W, Vidal JE, Grijalva CG, et al. Density interactions among Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus in the nasopharynx of young Peruvian children. Pediatr Infect Dis J 2013;32:72–7.
    1. Fukumoto H, Sato Y, Hasegawa H, et al. Development of a new real-time PCR system for simultaneous detection of bacteria and fungi in pathological samples. Int J Clin Exp Pathol 2015;8:15479–88.
    1. Montassier E, Gastinne T, Vangay P, et al. Chemotherapy-driven dysbiosis in the intestinal microbiome. Aliment Pharmacol Ther 2015;42:515–28.
    1. Tap J, Mondot S, Levenez F, et al. Towards the human intestinal microbiota phylogenetic core. Environ Microbiol 2009;11:2574–84.
    1. Hilty M, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic airways. PLoS One 2010;5:e8578doi:10.1371/journal.pone.0008578.
    1. Wild BWS and CP. World Cancer Report 2014.; 2014. doi:9283204298.
    1. Aisner DL, Marshall CB. Molecular pathology of non-small cell lung cancer: a practical guide. Am J Clin Pathol 2012;138:332–46.
    1. Travis W, Brambilla E, Muller-Mermelink H, et al. Patology and genetics of tumours of the lung, pleura, thyumus and heart. IARC Pres 2004;10:1–344.
    1. Miller YE. Pathogenesis of lung cancer. Am J Respir Cell Mol Biol 2005;33:216–23.
    1. Dickson RP, Erb-Downward JR, Huffnagle GB. The role of the bacterial microbiome in lung disease. Expert Rev Respir Med 2013;7:245–57.
    1. He Y, Wen Q, Yao F, et al. Gut–lung axis: the microbial contributions and clinical implications. Crit Rev Microbiol 2016;0:1–5.
    1. Tsay T-B, Yang M-C, Chen P-H, et al. Gut flora enhance bacterial clearance in lung through toll-like receptors 4. J Biomed Sci 2011;18:68.
    1. Gui Q-F, Lu H-F, Zhang C-X, et al. Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model. Genet Mol Res 2015;14:5642–51.
    1. Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018;359:97–103.
    1. Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013;342:971–6.
    1. Dzutsev A, Goldszmid RS, Viaud S, et al. The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. Eur J Immunol 2015;45:17–31.
    1. Goubet A-GL, Daillè R, Routy B, et al. The impact of the intestinal microbiota in therapeutic responses against cancer. C R Biol 2018;341:284–9.
    1. Kostic AD, Chun E, Robertson L, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013;14:207–15.
    1. Blander JM, Longman RS, Iliev ID, et al. Regulation of inflammation by microbiota interactions with the host. Nat Immunol 2017;18:851–60.
    1. Eberhardt WE, Mitchell A, Crowley J, et al. The IASLC lung cancer staging project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol 2015;10:1515–22.
    1. Eftimiadi C, Tonetti M, Cavallero A, et al. Short-chain fatty acids produced by anaerobic bacteria inhibit phagocytosis by human lung phagocytes. J Infect Dis 1990;161:138–42.
    1. Erb-Downward JR, Thompson DL, Han MK, et al. Analysis of the lung microbiome in the “Healthy” smoker and in COPD. PLoS One 2011;6:e16384doi:10.1371/journal.pone.0016384.
    1. Sze MA, Dimitriu PA, Hayashi S, et al. The lung tissue microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185:1073–80.
    1. Pang T, Leach ST, Katz T, et al. Fecal biomarkers of intestinal health and disease in children. Front Pediatr 2014;2:6doi:10.3389/fped.2014.00006.
    1. Cuervo A, Salazar N, Ruas-Madiedo P, et al. Fiber from a regular diet is directly associated with fecal short-chain fatty acid concentrations in the elderly. Nutr Res 2013;33:811–6.
    1. Sanmamed MF, Carranza-Rua O, Alfaro C, et al. Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins. Clin Cancer Res 2014;20:5697–707.
    1. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013;14:218–28. doi:10.1016/S1470-2045(12)70582-X.
    1. Biagi E, Nylund L, Candela M, et al. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS One 2010;5: doi:10.1371/journal.pone.0010667.
    1. Yu J. Intestinal stem cell injury and protection during cancer therapy. Transl Cancer Res 2013;2:384–96.
    1. Beck PL, Wong JF, Li Y, et al. Chemotherapy- and radiotherapy-induced intestinal damage is regulated by intestinal trefoil factor. Gastroenterology 2004;126:796–808.
    1. Chaveli-López B, Bagán-Sebastián JV. Chemotherapy-induced oral mucositis treatment treatment of oral mucositis due to chemotherapy. J Clin Exp Dent 2016;8:201–10.
    1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN. Int J cancer 2015;136:E359–86.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅